Manufacturing & Packaging

Two months after tornado strikes North Carolina facility, manufacturing will undergo a phased approach, with full capacity expected by the end of 2023.

CDMO purchases branded sachet-packaging machine for commercial manufacturing.

The insulated shipping containers can be used in the pharma industry and are reportedly environmentally friendly.

Deal to focus on development and commercialization in key emerging countries.

Deal aims to provide diabetes treatment to patients across the continent.

SaaS’ branded platform expected to help grow manufacturer’s therapeutic development processes.

CDMO will continue to produce commercial antibody cancer drug substance, featuring a new $242 million agreement.

The draft guidance document discusses the development of labeling for proposed biosimilars and interchangeable biosimilars for submission under section 351(k) of the Public Health Service Act.

Financial commitment is intended to benefit development and commercialization of new products.

Further expansions of the pharmaceutical development and manufacturing services of ten23 are happening at the BASE and VIVA facilities to continue to support complex sterile product development, testing, and manufacturing.

How drugmakers can navigate the program’s pricing challenges and regulatory developments.

Expansion allows facility to provide E2E services in one location, including commercial manufacturing.

The company will occupy approximately 62,000 square feet of the new building.

The plant— dedicated to cell and gene therapy development—welcomes additional warehouse space, and aims to meet commercial needs.

How the ‘fight-for-the-dollar’ is coming and likely will impact the bundled pricing of industry stakeholders.

Companies' emphasis on delivering pharmaceuticals is evolving into a collaboration focused on healthcare outcomes.

The key questions and considerations for drug manufacturers pursuing an effective alternative distribution model.

CDMO’s Taoyuan City plant is set to provide customers with products ranging from emulsions to gels.

CDMO’s Turku addition will span over 69,000 square feet and support the production of ATMPs.

Sterile injectable plant—struck by tornado—is currently being assessed.

The 19,500 square-foot warehouse will support API manufacturing activities, all the way through commercialization.

The debut will be the CDMO’s first fully automated sterile injectable manufacturing line at the Wuxi, China site.

Report reiterates CDMO’s commitment to net-zero emissions.

Goal of the deal is to boost the production of oral dosage forms.

The 50,000 square-foot facility will feature 10 new manufacturing sites with commercial capabilities.